Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells:: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect

被引:26
作者
Glass, B [1 ]
Nickelsen, M [1 ]
Dreger, P [1 ]
Claviez, A [1 ]
Hasenkamp, J [1 ]
Wulf, G [1 ]
Trümper, L [1 ]
Schmitz, N [1 ]
机构
[1] Univ Hosp Gottingen, Dept Hematol & Oncol, D-37075 Gottingen, Germany
关键词
graft-verus-lymphoma; lymphoma; allogeneic SCT; reduced-intensity conditioning;
D O I
10.1038/sj.bmt.1704600
中图分类号
Q6 [生物物理学];
学科分类号
071011 [生物物理学];
摘要
In patients with poor-risk relapse of aggressive lymphoma, reduced-intensity conditioning followed by allogeneic PBSCT may have its limitations because of rapid regrowth of the tumor. We tried to address this problem by intermediate-intensity conditioning followed by allogeneic SCT. A total of 21 patients received fludarabine, busulfan and cyclophosphamide prior to allogeneic SCT. In the first 10 patients, GVHD prophylaxis by CD34+ selection of the grafts was employed (group I). The next 11 patients received nonmanipulated grafts and mycophenolat mofetil plus cyclosporinA (group II). In group I, no GVHD was observed. In contrast, patients in group II had a significant risk of acute GVHD (aGVHD) (six patients with grade II-IV acute GVHD). However, in group I, all surviving patients progressed within 9 months. In contrast, eight of nine surviving patients of group II remain in remission after a median observation time of 10.5 months (range 4-22 months). Survival differed significantly between the groups (P = 0.004). Multivariate analysis identified intensive GVHD prophylaxis as important risk factor for survival. These results support the existence of a clinically relevant GVL effect in aggressive lymphoma. T-cell depletion (or CD34 selection) of grafts is not recommended in patients with poor-risk aggressive NHL.
引用
收藏
页码:391 / 397
页数:7
相关论文
共 24 条
[1]
Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens [J].
Bertz, H ;
Illerhaus, G ;
Veelken, H ;
Finke, J .
ANNALS OF ONCOLOGY, 2002, 13 (01) :135-139
[2]
Blay JY, 1998, BLOOD, V92, P3562
[3]
Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies [J].
Branson, K ;
Chopra, R ;
Kottaridis, PD ;
McQuaker, G ;
Parker, A ;
Schey, S ;
Chakraverty, RK ;
Craddock, C ;
Milligan, DW ;
Pettengell, R ;
Marsh, JCW ;
Linch, DC ;
Goldstone, AH ;
Williams, CD ;
Mackinnon, S .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (19) :4022-4031
[4]
BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: Analysis of efficacy, toxicity and prognostic factors [J].
Caballero, MD ;
Rubio, V ;
Rifon, J ;
Heras, I ;
GarciaSanz, R ;
Vazquez, L ;
Vidriales, B ;
delCanizo, MC ;
Corrall, M ;
Gonzalez, M ;
Leon, A ;
JeanPaul, E ;
Rocha, E ;
Moraleda, JM ;
SanMiguel, JF .
BONE MARROW TRANSPLANTATION, 1997, 20 (06) :451-458
[5]
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies [J].
Corradini, P ;
Tarella, C ;
Olivieri, A ;
Gianni, AM ;
Voena, C ;
Zallio, F ;
Ladetto, M ;
Falda, M ;
Lucesole, M ;
Dodero, A ;
Ciceri, F ;
Benedetti, F ;
Rambaldi, A ;
Sajeva, MR ;
Tresoldi, M ;
Pileri, A ;
Bordignon, C ;
Bregni, M .
BLOOD, 2002, 99 (01) :75-82
[6]
Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT [J].
Dreger, P ;
Glass, B ;
Seyfarth, B ;
Humpe, A ;
Claviez, A ;
von Neuhoff, N ;
Suttorp, M ;
Schoch, R ;
Schmitz, N .
BONE MARROW TRANSPLANTATION, 2000, 26 (12) :1361-1362
[7]
GLASS B, 2002, BONE MARROW TRANS S2, V29
[8]
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial [J].
Guglielmi, C ;
Gomez, F ;
Philip, T ;
Hagenbeek, A ;
Martelli, M ;
Sebban, C ;
Milpied, N ;
Bron, D ;
Cahn, JY ;
Somers, R ;
Sonneveld, P ;
Gisselbrecht, C ;
Van der Lelie, H ;
Chauvin, F .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) :3264-3269
[9]
Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma [J].
Hänel, M ;
Kröger, N ;
Sonnenberg, S ;
Bornhäuser, M ;
Krüger, W ;
Kroschinsky, F ;
Hänel, A ;
Metzner, B ;
Birkmann, J ;
Schmid, B ;
Hoffknecht, MM ;
Fiedler, F ;
Ehninger, G ;
Zander, AR .
ANNALS OF HEMATOLOGY, 2002, 81 (02) :96-102
[10]
New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group [J].
Josting, A ;
Franklin, J ;
May, M ;
Koch, P ;
Beykirch, MK ;
Heinz, J ;
Rudolph, C ;
Diehl, V ;
Engert, A .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :221-230